SecurityINSE / Inspired Entertainment, Inc. (45782N108)
CEO and PresidentAlvarez Luke Lyon
Institutional Owners40
Institutional Shares7,235,311 - 33.68%
Common Shares Outstanding21,484,707 shares (as of 2018-03-31)
Institutional Value$ 71,750,000 USD
Related HDRA / Hydra Industries Acquisition Corp.
HDRAR / Hydra Industries Acquisition Corp.
HDRAW / Hydra Industries Acquisition Corp.
HDRAU / Hydra Industries Acquisition Corp.

Institutional Stock Ownership and Shareholders()

INSE / Inspired Entertainment, Inc. Institutional Ownership

Inspired Entertainment, Inc. (NASDAQ:INSE) has 40 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 7,235,311 shares. Largest shareholders include HG Vora Capital Management, LLC, AWM Investment Company, Inc., 683 Capital Management, LLC, Vanguard Group Inc, BlackRock Inc., Millennium Management Llc, Royce & Associates LLC, Penn Capital Management Co Inc, Geode Capital Management, Llc, and Northern Trust Corp.
Inspired Entertainment, Inc. (NASDAQ:INSE) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/inse"><img src="https://images.fintel.io/us-inse-so.png" alt="INSE / Inspired Entertainment, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-11 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 212 1
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 5,252 11,803 124.73 51 65 27.45
2018-05-14 13F-HR ARES MANAGEMENT LLC 565,193 0 -100.00 5,542 0 -100.00
2018-05-15 13F-HR UBS Group AG 805 0 -100.00 8 0 -100.00
2018-05-14 13F-HR MORGAN STANLEY 8,257 35,124 325.38 81 193 138.27
2018-05-09 13F-HR NORTHERN TRUST CORP 28,731 72,542 152.49 281 399 41.99
2018-05-15 13F-HR DEUTSCHE BANK AG\ 23,320 12,287 -47.31 227 67 -70.48
2018-05-09 13F-HR BlackRock Inc. 175,515 250,467 42.70 1,720 1,378 -19.88
2018-05-11 13F-HR Delpha Capital Management, Llc 9 0 -100.00 0 0
2018-04-20 13F-HR STRS OHIO 1,100 1,100 0.00 10 6 -40.00
2018-05-15 13F-HR JANE STREET GROUP, LLC 25,370 140
2018-05-10 13F-HR JP Morgan Chase & Co 847 3,494 312.51 8 20 150.00
2018-05-15 13F-HR STATE STREET CORP 39,763 50,025 25.81 391 278 -28.90
2018-05-11 13F-HR CITIGROUP INC 3,917 16,536 322.16 38 91 139.47
2018-05-11 13F-HR PENN CAPITAL MANAGEMENT CO INC 104,977 577
2018-05-15 13F-HR 683 Capital Management, LLC 298,209 614,319 106.00 2,922 3,379 15.64
2018-05-07 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 23,200 128
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 1,029 1,004 -2.43 10 6 -40.00
2017-02-10 13F-HR BlackRock Advisors LLC 3,053 26
2018-05-14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 6,609 0 -100.00 65 0 -100.00
2018-05-14 13F-HR Royce & Associates LLC 110,000 605
2018-05-14 13F-HR TEACHERS ADVISORS INC 5,294 0 -100.00 52 0 -100.00
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 469 724 54.37 4 4 0.00
2018-05-15 13F-HR BlueMar Capital Management, LLC 51,279 282
2018-05-10 13F-HR AWM Investment Company, Inc. 984,937 5,417
2018-05-15 13F-HR Parallax Volatility Advisers, L.P. 588 0 -100.00 6 0 -100.00
2018-05-14 13F-HR Renaissance Technologies LLC 15,900 0 -100.00 156 0 -100.00
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 0 36,084 0 198
2018-05-14 13F-HR Laurion Capital Management LP 21,325 117
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 15,536 224,187 1,343.02 152 1,233 711.18
2018-05-15 13F-HR Ameritas Investment Partners, Inc. 348 348 0.00 3 2 -33.33
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 622 0 -100.00 6 0 -100.00
2018-05-11 13F-HR BNP PARIBAS ARBITRAGE, SA 814 2,787 242.38 7,977 15,328 92.15
2018-05-10 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 5,600 5,600 0.00 55 31 -43.64
2018-05-10 13F-HR Spark Investment Management LLC 16,800 92
2018-05-15 13F-HR CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 6,300 14,685 133.10 62 81 30.65
2018-05-15 13F-HR Bank of New York Mellon Corp 15,531 16,216 4.41 152 89 -41.45
2018-05-15 13F-HR BARCLAYS PLC 628 1,996 217.83 6 11 83.33
2018-05-07 13F-HR AMERICAN INTERNATIONAL GROUP INC 2,671 6,164 130.77 26 34 30.77
2018-05-15 13F-HR VANGUARD GROUP INC 492,766 598,325 21.42 4,829 3,291 -31.85
2018-05-17 13F-HR Legal & General Group Plc 959 959 0.00 9 5 -44.44
2018-05-11 13F-HR Russell Investments Group, Ltd. 58,649 323
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 1,449 637 -56.04 14 4 -71.43
2018-05-11 13F-HR MACQUARIE GROUP LTD 29,633 16,631 -43.88
2018-04-30 13F-HR James Hambro & Partners 9,546 52
2018-05-03 13F-HR MEEDER ASSET MANAGEMENT INC 241 1
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 24,081 98,309 308.24 235 540 129.79
2018-05-15 13F-HR HG Vora Capital Management, LLC 2,506,500 3,750,000 49.61 24,564 20,625 -16.04

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

9h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

9h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

BRIEF-Inspired Announces Content Deal With Novomatic

2018-04-25 reuters
* INSPIRED ENTERTAINMENT INC - HAS SIGNED AN AGREEMENT TO SUPPLY ITS GAMES CONTENT TO NOVOMATIC’S ITALIAN GAMING PLATFORM

CUSIP: 45782N108